| Company/Division name | AbbVie |
| Parent company | AbbVie |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2025 |
| Year reshoring implemented or to be implemented: | 2027 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 195 |
| City reshored to: | Chicago |
| State(s) reshored to: | IL |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | Pharmaceuticals |
| What domestic positive factors made reshoring more attractive? | Eco-system synergies, Impact on domestic economy, Proximity to customers/market |
